Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

1/30/24 7:07:59 AM ET

$BBIO

$NVTA

Biotechnology: Pharmaceutical Preparations

Health Care

Medical Specialities

Health Care

Get the next $BBIO alert in real time by email

Invitae (NYSE:NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.

Get the next $BBIO alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$BBIO
$NVTA

Company	Date	Price Target	Rating	Analyst
BridgeBio Pharma Inc. $BBIO	3/10/2026		Outperform	William Blair
BridgeBio Pharma Inc. $BBIO	1/28/2026	$157.00	Overweight	Barclays
BridgeBio Pharma Inc. $BBIO	1/6/2026	$96.00	Overweight	Morgan Stanley
BridgeBio Pharma Inc. $BBIO	12/11/2025	$94.00	Outperform	Bernstein
BridgeBio Pharma Inc. $BBIO	7/30/2025	$56.00	Outperform	Raymond James
BridgeBio Pharma Inc. $BBIO	7/21/2025	$66.00	Buy	Truist
BridgeBio Pharma Inc. $BBIO	7/14/2025	$70.00	Buy	Jefferies
BridgeBio Pharma Inc. $BBIO	7/9/2025	$60.00	Perform → Outperform	Oppenheimer

More analyst ratings

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$BBIO
$NVTA

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$BBIO
$NVTA

$BBIO
$NVTA
FDA approvals

FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

$BBIO
$NVTA
Insider Trading

SEC Form 4 filed by Trimarchi Thomas

SEC Form 4 filed by Apuli Maricel

SEC Form 4 filed by Kumar Neil

$BBIO
$NVTA
Press Releases

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

$BBIO
$NVTA
SEC Filings

Amendment: SEC Form SCHEDULE 13D/A filed by BridgeBio Pharma Inc.

BridgeBio Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by BridgeBio Pharma Inc.

$BBIO
$NVTA
Analyst Ratings

William Blair initiated coverage on BridgeBio Pharma

Barclays initiated coverage on BridgeBio Pharma with a new price target

Morgan Stanley initiated coverage on BridgeBio Pharma with a new price target

$BBIO
$NVTA
Insider Purchases

Amendment: Director Valantine Hannah bought $24,948 worth of shares (1,752 units at $14.24), increasing direct ownership by 114% to 3,294 units (SEC Form 4)

Amendment: Director Valantine Hannah bought $30,028 worth of shares (2,338 units at $12.84) (SEC Form 4)

Valantine Hannah bought $44,476 worth of shares (3,433 units at $12.96) (SEC Form 4)

$BBIO
$NVTA
Financials

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia

$BBIO
$NVTA
Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

$BBIO
$NVTA
Leadership Updates

BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

Aranscia Acquires YouScript from Invitae

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $BBIO$NVTA

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $BBIO$NVTA

$BBIO$NVTA FDA approvals

FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

$BBIO$NVTA Insider Trading

SEC Form 4 filed by Trimarchi Thomas

SEC Form 4 filed by Apuli Maricel

SEC Form 4 filed by Kumar Neil

$BBIO$NVTA Press Releases

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

$BBIO$NVTA SEC Filings

Amendment: SEC Form SCHEDULE 13D/A filed by BridgeBio Pharma Inc.

BridgeBio Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by BridgeBio Pharma Inc.

$BBIO$NVTA Analyst Ratings

William Blair initiated coverage on BridgeBio Pharma

Barclays initiated coverage on BridgeBio Pharma with a new price target

Morgan Stanley initiated coverage on BridgeBio Pharma with a new price target

$BBIO$NVTA Insider Purchases

Amendment: Director Valantine Hannah bought $24,948 worth of shares (1,752 units at $14.24), increasing direct ownership by 114% to 3,294 units (SEC Form 4)

Amendment: Director Valantine Hannah bought $30,028 worth of shares (2,338 units at $12.84) (SEC Form 4)

Valantine Hannah bought $44,476 worth of shares (3,433 units at $12.96) (SEC Form 4)

$BBIO$NVTA Financials

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia

$BBIO$NVTA Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

$BBIO$NVTA Leadership Updates

BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

Aranscia Acquires YouScript from Invitae

Recent Analyst Ratings for
$BBIO
$NVTA

Recent Analyst Ratings for
$BBIO
$NVTA

$BBIO
$NVTA
FDA approvals

$BBIO
$NVTA
Insider Trading

$BBIO
$NVTA
Press Releases

$BBIO
$NVTA
SEC Filings

$BBIO
$NVTA
Analyst Ratings

$BBIO
$NVTA
Insider Purchases

$BBIO
$NVTA
Financials

$BBIO
$NVTA
Large Ownership Changes

$BBIO
$NVTA
Leadership Updates